The next controversy in genetic testing: Clinical data as trade secrets?

European Journal of Human Genetics

Volumn 21, Issue 6, 2013, Pages 585-588

  Cook Deegan, Robert ^a,b   Conley, John M ^c,d   Evans, James P ^e   Vorhaus, Daniel ^d  

^a DUKE UNIVERSITY   (United States)

^b Fondation Brocher   (Switzerland)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Robinson Bradshaw and Hinson PA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ALGORITHM; ARTICLE; CLINICAL STUDY; DATA BASE; ELECTRONIC MEDICAL RECORD; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE PERSONNEL; HUMAN; MEDICAL INFORMATION; MEDICAL SOCIETY; MISSENSE MUTATION; ORGANIZATION AND MANAGEMENT; PATENT; PERSONALIZED MEDICINE; PHENOTYPE; POLICY; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLICATION; REIMBURSEMENT; CONFIDENTIALITY; ECONOMICS; ETHICS; INFORMATION DISSEMINATION;

CONFIDENTIALITY; GENETIC TESTING; GENETIC VARIATION; HUMANS; INFORMATION DISSEMINATION; PUBLIC POLICY;

EID: 84883100680     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.217     Document Type: Article

References (20)

1. Myriad Genetics I. Written Comments on Genetic Diagnostic Testing Study (the Statement About One Million Tests is on Page 20; the 3 Percent VUS Rate for US Versus 20 Percent for Europe is Attributed to a Market Research Report Cited on Page 23). Salt Lake City, UT. Written statement supplementing oral testimony to the US Patent and Trademark Office pursuant to Section 27 of the America Invents Act of 2011, 2012; 27.
2. DaviesK, WhiteM: Breakthrough: The Race to Find the Breast Cancer Gene. New York: John Wiley, 1996.
3. Gold ER, Carbone J. Myriad genetics: in the eye of the policy storm. Genet Med. 2010; 12:4 Suppl S39-S70.
4. Parthasarathy S. Building Genetic Medicine: Breast Cancer, Technology, and the Comparative Politics of Health Care. Cambridge, MA. MIT Press, 2007.
5. Cho MK, Illangasekare S, Weaver MA, Leonard DG, Merz JF. Effects of patents and licenses on the provision of clinical genetic testing services. J Mol Diagn. 2003; 5: 3-8.
6. Myriad Genetics I. Form 10-Q: Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended Septembera 30, 2011. Salt Lake City, Utah: Myriad Genetics, Inc, 2011.
7. Hopkins MM, Nightingale P. Strategic risk management using complementary assets: organizational capabilities and the commercialization of human genetic testing in the UK. Res Policy. 2006; 35: 355-374.
8. UK Human Genetic Commission: Intellectual Property and DNA Diagnostics. London: Human Genetics Commission, 2010.
9. Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1, 433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007; 81: 873-883.
10. Eisenbraun A, Wenstrup R, Hellerstedt B, et al. Hereditary breast and ovarian cancer testing: integration and outcomes within community oncology practices. Commun Oncol. 2010; 7: 75-81.
11. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009; 115: 2222-2233.
12. Saam JBL, Bowles K, Roa B, et al. Decline in rate of BRCA1/2 variants of uncertain significance: 2002-2008. 27th Annual Education Conference of the National Society of Genetic Counselors. Los Angeles, CA 2008.
13. Wu K, Hinson SR, Ohashi A, et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 2005; 65: 417-426.
14. Micheel CM, Nass SJ, Omenn GS (eds Evolution of Translational Omics: Lessons Learned and the Path Forward. National Academies Press, 2012.
15. National Research Council: Sharing Publication-Related Data and Materials: Responsibilities of Authorship in the Life Sciences. Washington, DC. National Academies Press, 2003.
16. MutaDATABASE. 'Participating Laboratories' and 'Non-Participating Laboratories' lists at www.mutadatabase.org and personal communication, Patrick Willems, 18 April 2012; in Willems P, (ed.): MutaDATABASE website. Belgium, 2012.
17. Lindor NM, Guidugli L, Wang X, et al. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat. 2012; 33: 8-21.
18. Radice P, De Summa S, Caleca L, Tommasi S. Unclassified variants in BRCA genes: guidelines for interpretation. Ann Oncol. 2011; 22:Suppl 1 i18-i23.
19. Tommasi S, De Summa S, Pilato B, Paradiso A. BRCA unclassified variants: how can they be classified?. Curr Women Health Rev. 2012; 8: 30-37.
20. International Committee of Medical Journal Editors: Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication, 2010.